Hollow Mesoporous Selenium Nanoparticles Loaded with Pyrotinib and Coated with Trastuzumab-Functionalized Albumin for Targeted Therapy of HER2-Positive Breast Cancer
Source abstract
Abstract
This study aimed to develop trastuzumab (HCT)-functionalized albumin (BSA)-coated, pyrotinib (Ptb)-loaded hollow mesoporous selenium (HSE) nanoparticles (HBHSEP) for the targeted delivery of HER2-positive breast cancer. Characterization of the pharmaceutical properties in vitro revealed that HBHSEP was well dispersed, and the particle size was 172 ± 3.4 nm. In vitro release experiments revealed that HBHSEP effectively controlled the release of Ptb in the tumor microenvironment (high glutathione concentration), with a cumulative release rate of 86.5 ± 4.2% over 48 h. Cell uptake experiments and in vivo imaging confirmed that HBHSEP have good tumor-targeting ability. The results of in vitro cell experiments, such as MTT, flow cytometry, immunofluorescence staining, and in vivo antitumor experiments, confirmed that HBHSEP can significantly promote the apoptosis of SK-BR-3 cells and inhibit their proliferation. These findings strongly show that HBHSEP may be an effective targeted treatment for HER2-positive breast cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Carbon and Quantum Dots Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Pharmacy School, Jinzhou Medical University, 40 Songpo Road, Linghe, Jinzhou, Liaoning 121001, China
Department of Medical Oncology, The First Affiliated Hospital of Jinzhou Medical University, No. 2, The Fifth Section of Renmin Street, Guta District, Jinzhou, Liaoning Province 121001, China
Funding
Basic scientific research projects in universities · Special fund for basic scientific research business expenses of undergraduate universities in Liaoning Province · Liaoning Province Applied Basic Research Program Joint Project · Scientific Research Project of the Educational Department of Liaoning Province · Liaoning Provincial Key Laboratory of Marine Bioactive Substances and Technological Innovation Center of Liaoning Pharmaceutical Action and Quality Evaluation · Jinzhou City Guiding Science and Technology Planning Project · Youth project
References (51)
Show source-provided references
1. 10.1002/cac2.1238710.1002/cac2.12387 ↗
2. 10.1016/j.critrevonc.2024.10435110.1016/j.critrevonc.2024.104351 ↗
3. 10.1002/cncr.3310210.1002/cncr.33102 ↗
4. 10.1016/j.drup.2024.10107810.1016/j.drup.2024.101078 ↗
5. 10.1002/jcp.2921610.1002/jcp.29216 ↗
6. 10.1038/s41572-019-0111-210.1038/s41572-019-0111-2 ↗
7. 10.1038/s41573-022-00579-010.1038/s41573-022-00579-0 ↗
8. 10.1177/1758835921101332610.1177/17588359211013326 ↗
9. Esteva F. J. · Oncology (Williston Park) · 2002 · 16 · 17
10. 10.3892/etm.2021.1103710.3892/etm.2021.11037 ↗
11. 10.3389/fphar.2022.108906610.3389/fphar.2022.1089066 ↗
12. Xuhong J. C. · Am. J. Cancer Res. · 2019 · 9 · 2103
13. 10.1186/s13058-023-01694-510.1186/s13058-023-01694-5 ↗
14. 10.1016/j.ejca.2021.06.02610.1016/j.ejca.2021.06.026 ↗
15. 10.1097/CAD.000000000000160410.1097/CAD.0000000000001604 ↗
16. 10.1007/s11033-023-08809-310.1007/s11033-023-08809-3 ↗
17. 10.3390/pharmaceutics1504118110.3390/pharmaceutics15041181 ↗
18. 10.3390/polym1510231710.3390/polym15102317 ↗
19. 10.1186/s12951-023-02064-110.1186/s12951-023-02064-1 ↗
20. 10.1016/j.colsurfb.2024.11375810.1016/j.colsurfb.2024.113758 ↗
21. 10.1021/acsnano.3c0929310.1021/acsnano.3c09293 ↗
22. 10.1038/s41392-023-01642-x10.1038/s41392-023-01642-x ↗
23. 10.3390/pharmaceutics1312207010.3390/pharmaceutics13122070 ↗
24. 10.2174/011381612829732924030507110310.2174/0113816128297329240305071103 ↗
25. 10.3389/fnut.2023.118348710.3389/fnut.2023.1183487 ↗
26. 10.1186/s12951-023-01825-210.1186/s12951-023-01825-2 ↗
27. 10.3390/ijms22211184410.3390/ijms222111844 ↗
28. 10.2174/187152062266622021512275610.2174/1871520622666220215122756 ↗
29. 10.1186/s12951-016-0243-410.1186/s12951-016-0243-4 ↗
30. 10.3390/nu1203085710.3390/nu12030857 ↗
31. 10.3390/biomimetics802025910.3390/biomimetics8020259 ↗
32. 10.2147/IJN.S23708910.2147/IJN.S237089 ↗
33. 10.2217/nnm-2017-002410.2217/nnm-2017-0024 ↗
34. 10.1186/s12951-017-0324-z10.1186/s12951-017-0324-z ↗
35. 10.1016/j.ijbiomac.2019.02.12910.1016/j.ijbiomac.2019.02.129 ↗
36. 10.1016/j.colsurfb.2023.11320110.1016/j.colsurfb.2023.113201 ↗
37. 10.1016/j.actbio.2017.02.04210.1016/j.actbio.2017.02.042 ↗
38. 10.1016/j.ijbiomac.2019.02.12910.1016/j.ijbiomac.2019.02.129 ↗
39. 10.1016/j.apsb.2021.09.02410.1016/j.apsb.2021.09.024 ↗
40. 10.1016/j.carbpol.2020.11598110.1016/j.carbpol.2020.115981 ↗
41. 10.1186/s13058-021-01459-y10.1186/s13058-021-01459-y ↗
42. 10.3389/fonc.2022.100642910.3389/fonc.2022.1006429 ↗
43. 10.1159/00052875610.1159/000528756 ↗
44. 10.1159/00051232810.1159/000512328 ↗
45. 10.1186/s12951-024-02540-210.1186/s12951-024-02540-2 ↗
46. 10.1021/acsbiomaterials.3c0100910.1021/acsbiomaterials.3c01009 ↗
47. 10.1038/s41573-022-00579-010.1038/s41573-022-00579-0 ↗
48. 10.1016/j.ctrv.2022.10250010.1016/j.ctrv.2022.102500 ↗
49. 10.1016/j.biomaterials.2020.12025310.1016/j.biomaterials.2020.120253 ↗
50. 10.1016/j.actbio.2017.02.04210.1016/j.actbio.2017.02.042 ↗
51. 10.1016/j.ijbiomac.2023.12326110.1016/j.ijbiomac.2023.123261 ↗